Core Viewpoint - The stock of He Yu-B (02256) has risen over 4%, reaching a historical high of 13.67 HKD, with a year-to-date increase of nearly 100% [1] Financial Performance - For the first half of the year, the company reported revenue of 612 million RMB, representing a year-on-year growth of 21.5% [1] - The net profit attributable to shareholders was 328 million RMB, showing a significant increase of 58.8% year-on-year [1] Research and Development - The company has increased its R&D expenses by 6% year-on-year, while reducing management fees by 13%, leading to improved profitability [1] Financial Guidance - The company has guided that its operating cash consumption for the year will remain within 570 million RMB, with expectations of maintaining profitability [1] Market Valuation - Citigroup believes that the current valuation of He Yu is low, considering the high certainty of its two late-stage drug candidates, pimicotinib and irpagratinib, and the potential for differentiated innovative pipelines to achieve external licensing [1] Future Catalysts - Key catalysts are anticipated in 2025 and 2026, including the approval and commercialization of pimicotinib, the release of phase III data for irpagratinib in second-line liver cancer, and updates on several other drug candidates [1]
港股异动 和誉-B(02256)再涨超4% 股价续刷历史新高 年内股价累涨近两倍